HemoTypeSC Has a CE Mark and is Registered in India, Ghana, Nigeria, Kenya, and Saudi Arabia

ASH Videos


Pre-Release Press Conference to Discuss Uganda Validation Study Data

November 13, 2019

"If [HemoTypeSC] were to be widely implemented in newborn screening initiatives in sub-Saharan Africa and India, it could significantly reduce the mortality of the disease when combined with both treatment and counseling. This would potentially save millions of lives over several decades."
Read More

ASH Clinical News Interview - HemoTypeSC Late-Breaking Abstract

December 14, 2018

Erik Serrao discusses the data from a recently-completed field validation trial in southeastern Uganda.  In this collaboration with the Sickle Cell Association of Uganda, led by Ruth Nankanja, HemoTypeSC correctly identified the hemoglobin type of 1,000 out of 1,000 children screened.

Read More